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Abstract
AIM: To assess the clinical presentation and genotypes 
of delta hepatitis in local population.
METHODS: In this prospective study, 39 consecutive 
patients who were positive for HBsAg and hepatitis 
D virus (HDV) antibody were included. The patients 
were divided in two groups on the basis of presence 
or absence of HDV RNA and a comparative study was 
done. Genotype of HDV was determined in PCR positive 
patients.
RESULTS: Overall there is male dominance, in which 
34 patients out of 39 (87.2%) were male. Twenty 
(51%) patients were from the adjacent areas of three 
provinces; Sindh, Punjab and Balochistan indicating the 
higher prevalence of delta hepatitis in this mid region 
of Pakistan. Patients of all age groups were affected 
with delta hepatitis (median 31.5 years, range 12-75). 
HDV RNA was detectable in 23 patients (59%). All 
the HDV strains belonged to genotype I. HBV DNA 
was detectable only in 3 cases who were also HBeAg 
and HDV RNA positive. Patients with detectable HDV 
RNA were younger than patients with undetectable 
RNA; mean age 29.7 ± 12.8 years vs  36.8 ± 15.2. 
There were no statistically significant differences in the 
clinical presentation and routine biochemical profile 
of patients with detectable or undetectable HDV RNA. 
Clinical cirrhosis was present in 19 (49%) patients; 12 
with detectable RNA and 7 with undetectable HDV RNA 
(P = 0.748). Decompensated disease was seen in eight 
patients; five and three respectively from each group. 
Four patients with undetectable RNA and two patients 
with detectable RNA had normal ALT and ultrasound 
abdomen.
CONCLUSION: HDV may infect at any age, usually 
young adult males. Genotype I  is prevalent. With 
time some of the patients become HDV RNA negative 
or asymptomatic carrier. Most of the patients have 
suppressed HBV DNA replication. Significant numbers of 
patients have cirrhosis.
© 2007 The WJG Press. All rights reserved.
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INTRODUCTION
Up to 5% of  the world's population is infected with 
hepatitis B virus (HBV), and probably 5% of  the HBV 
carriers have hepatitis D virus (HDV) superinfection[1]. It 
is estimated that 15 million people are infected with HDV 
worldwide[2]. Superinfection of  HDV in persons with 
HBV infection leads to progressive disease and cirrhosis 
in approximately 80% of  cases[3]. Cirrhosis develops at a 
younger age than in patients with chronic HBV infection 
alone[4].
In Pakistan viral hepatitis remains a serious health 
problem. Recent data suggested that 16.6% of  patients 
infected with hepatitis B virus also suffered from 
superimposed delta infection[5]. However, local data 
is based on serology of  HDV and PCR studies were 
not done. It is not clear how many of  local patients 
spontaneously recover from the infection and how these 
patients differ from patients with persistent infection. 
Moreover, the genotype of  the virus in Pakistan is also 
unknown.
The nucleotide sequences of  hepatitis D viruses (HDV) 
vary 5% to 14% among isolates of  the same genotype 
and 23% to 34% among different genotypes[6,7]. Based on 
the analysis of  HDV genomes from different areas of  
the world, three genotypes of  HDV have been identified. 
Genotype I  is the most prevalent worldwide and is 
associated with a broad spectrum of  pathogenecity. It is 
predominant in the Europe, United States and the Middle 
East and has some geographically based subtypes[7,8]. In 
the Far East, the predominant genotype is genotypeII. 
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Patients infected with this genotype have significantly 
lower ALT levels, more favorable outcomes and a trend 
to have lower serum HDV RNA levels as compared with 
those infected with genotype I [9]. However II b variant may 
be associated with progressive disease[10]. Type III genotype 
is predominant in northern South America and has been 
associated with severe forms of  hepatitis[11].
We evaluated our patients in terms of  genotype and 
prognosis and compared the HDV RNA positive patients 
with the negative group.
MATERIALS AND METHODS
Thirty nine patients who were HBsAg and HDV antibody 
positive for more than six months were further tested for 
HDV RNA. These patients were divided into two groups; 
the first group included a total of  23 patients which were 
HDV RNA positive by PCR reflecting active ongoing 
delta infection while the second group consisted of  a total 
of  16 patients with undetectable HDV RNA reflecting 
previous exposure to delta hepatitis or viral load less than 
the sensitivity of  assay used for the HDV RNA. Markers 
for hepatitis B activity were done in all of  these which 
included HBeAg, Anti-HBe antibody, and HBV DNA.
Extraction and RT-PCR analysis of HDV RNA
HDV RNA was isolated from patients' serum samples 
by High Pure Viral RNA isolation kit according to the 
manufacturer's instructions (Roche Diagnostics, USA). 
RNA was eluted from spin columns provided with the 
kit in sterile nuclease free water and stored at -80℃ 
until further analysis. Later, RNA samples were reverse 
transcribed into cDNA using 1st Strand cDNA Synthesis 
Kit for RT-PCR (Roche Diagnostics, USA). Briefly, cDNA 
mix consisted of  reaction buffer containing 5 mmol/L 
MgCl2, RNA, random primers, 50 units RNAse inhibitor 
and AMV reverse transcriptase. The reaction was carried 
out for 90 min at 42℃ in a thermal cycler. The resulting 
cDNA was amplified with sequence specific primers for 
HDV according to the published method[12]. The amplified 
products were separated on a 1.5% agarose gel and a 400 
bp product indicated the presence of  HDV in the sample. 
To monitor the quality of  the assay in each test run both 
negative and positive controls were included.
HDV genotyping by RT-PCR and RFLP assay
Serum samples of  patients which showed presence of  
HDV RNA were genotyped according to the pub-lished 
method of  Ivaniushia et al[13] 2000. After PCR amplification 
with primers specific for HDAg coding region, positive 
samples were digested overnight at 37℃ with restriction 
enzyme SmaI. Genotype I, II and III were confirmed and 
classified according the sizes of  the fragments following 
SamI digestion.
Extraction and amplification of HBV DNA
HBV DNA was extracted using High Pure Viral Nucleic 
Acid isolation assay as indicated by the manufacturer 
(Roche Diagnostics). Sequences of  primers, specific for 
core region of  HBV genome, used for amplification were 
previously reported[14]. Each PCR reaction consisted of  
reaction buffer, 0.2 mmol/L deoxyribonucleotides, 1.5 
mmol/L MgCl2, 100 ng of  each primer, and 2 U Taq 
polymerase in a final volume of  50 µL. All standard 
precautions were taken during the study to prevent cross 
contamination between PCR samples.
Serological tests
HBe 2.0 assay (Abbott, USA), which is based on microparticle 
enzyme immunoassay technology, was employed for the 
detection of  HBeAg levels in sera. For running the assay, 
the AxSYM system was used according to the manufacture's 
instruction (Abbott, USA). Anti-HDV antibody test was 
performed by Murex competitive enzyme immunoassay as 
suggested by the manufacturer (Abbott, Chicago IL, USA).
Clinical aspects
The clinical features of  patients with detectable HDV 
RNA were compared with HDV RNA negative patients 
to determine the clinical impact of  continuous presence 
of  HDV RNA and outcome for HDV infect ion. 
Informed consent was taken and a standardized pro 
forma was completed regarding laboratory and serological 
data, complications of  liver disease to include ascites, 
hematemesis and melena, portosystemic encephalopathy 
(PSE), hepatocellular carcinoma (HCC), and Childs-Pugh 
score. The study was approved by the Ethics Review 
Committee of  the Medicare Clinic.
The patients were labeled suffering from clinical 
cirrhosis on the basis of  clinical and ultrasound findings 
suggestive of  cirrhosis (nodular surface, firm consistency, 
blunt liver edge, altered echotexture, dilated portal vein 
and splenomegaly) and evidence of  hypersplenism (platelets 
< 15 000/mm3).
Statistical analysis
Results were analyzed using Special package for Social 
Sciences software (SPSS version 13.0, Chicago, IL, 
USA). Data was summarized as the means with standard 
deviations (for continuous variables), and as frequency 
and percentages (for categorical variables). Univariate 
analysis was done using Mann Whitney U-test, and Fischer 
exact test wherever appropriate. P < 0.05 was considered 
significant. All P-values were two sided.
RESULTS
Overall there is male dominance, in which 34 out of  39 
(87.2%) patients were male. These patients belonged to 
the different areas of  country. Of  those, 12 came from 
upper parts of  Sindh Province, 15 were from the lower 
Sindh including Karachi, 8 from Balochistan Province and 
4 from the lower parts of  Punjab Province. Out of  these, 
20 (51%) patients were from the adjoining districts of  
upper Sindh, Punjab and Balochistan Provinces. Patients 
of  all the age groups were affected with delta hepatitis, 
the disease was seen as early as the second decade of  life 
to as late as the mid 70's (range 12-75, median 31.5, mode 
22), but the majority of  patients in both the groups were 
adults.
The clinical presentation of  ant-HDV positive patients 
was jaundice in 11 (28%), ascites 3 (7.7%), encephalopathy 
3 (7.7%), and hematemesis 2 (5.1%). Nine patients 
gave the history of  hospitalization due to liver related 
indication. On examination the liver was palpable in 4 
(10.3%) and splenomegaly in 17 (43.6%). Laboratory 
investigations included hemoglobin 12.5 ± 1.9 g/dL, 
total leucocyte count 5.7 ± 2.0 × 109/L, platelets 151 ± 
66 × 109/L, INR 1.25 ± 0.16, bilirubin 2.2 ± 3.7 mg/dL, 
alanine aminotransferase (ALT) 103 ± 131 IU/L, aspartate 
aminotransferase (AST) 109 ± 179 IU/L, gamma glutamyl 
traspeptitase (GGT) 81 ± 101 IU/L, alkaline phosphatase 
116 ± 49 IU/L.
HDV RNA was detectable in 23 patients (59%). All of  
these patients belonged to genotype I  of  the virus. Viral 
markers of  hepatitis B replication, serum HBeAg and 
HBV DNA, were absent in a majority of  the cases in both 
the groups. HBV DNA was detectable only in 3 cases. 
These patients had HBeAg positive disease and were also 
positive for HDV RNA. None of  the HDV RNA negative 
patients were positive for HBV DNA though one such 
patient was positive for HBeAg.
Patients with detectable HDV RNA were younger than 
patients with undetectable RNA; age 29.7 ± 12.8 years 
vs 36.8 ± 15.2, though the difference was not statistically 
significant (95% CI-2.68-16.8). There was no statistically 
significant difference in the clinical presentation and 
routine biochemical profile of  patients with detectable or 
undetectable HDV RNA (Table 1). Clinical cirrhosis was 
present in 19 (49%) patients; 12 (52%) with detectable 
RNA and 7 (43%) with undetectable HDV RNA (P = 
0.748). Out of  these, decompensated disease (history of  
hematemesis, ascites, and encephalopathy) was seen in 8 
patients; 5 patients with detectable RNA and 3 without 
detectable HDV RNA. Four patients with undetectable 
RNA and 2 patients with detectable RNA had normal 
ALT and ultrasound abdomen. These 6 patients were HBV 
DNA and HBeAg negative.
DISCUSSION
Clinical studies of  HDV disease worldwide indicate 
that there is a wide variation in the clinical presentation. 
The manifestations of  HDV infection vary from benign 
acute hepatitis to fulminant hepatitis and from rapidly 
progressive chronic liver disease to an asymptomatic carrier 
state[15]. The clinical course was influenced by several 
factors, including the HDV genotype[9]. In our study all of  
the patients were infected with genotype I . This is new 
data from this region. Our previous study indicates, that in 
Pakistan, there is a predominant genotype of  Hepatitis B 
is genotype D[16]. The association of  genotype I  of  HDV 
with genotype D of  HBV has been reported from other 
countries where HBV genotype D is predominant as is in 
Italy[17], Turkey[18] and Egypt[19]. This genotype may cause a 
wide spectrum of  pathogenecity. In the South East Asia, 
the predominant HDV genotype is II and HBV genotype 
B and C. Genotype II is associated with a less rapidly 
progressive course of  chronic liver disease[9].
Local data regarding the hepatitis D strain is based 
upon presence of  anti-HDV antibody due to non-
availability of  PCR facility. The percentage of  patients who 
spontaneously recover from hepatitis D is not known. A 
recent study involving the clinical presentation of  hepatitis 
delta from Pakistan based on anti-HDV antibody, showed 
that HDV infection was present in 16.6% of  hepatitis B 
infected patients in Pakistan, most commonly in younger 
males living in rural areas. Delta antibody positive patients 
had less severe clinical liver disease compared to delta 
negative, hepatitis B patients[5]. HDV RNA status of  the 
patients was not known in that series. In our study again 
majority of  HDV antibody positive patients, 34 patients 
out of  39 (87.2%), were male. Most of  these patients were 
young adults and came from from upper part of  Sindh, 
lower Punjab and adjacent areas of  Balochistan Province. 
These adjoining areas of  three provinces form the 
hepatitis belt in Pakistan, the area with higher prevalence 
of  hepatitis. In our study, clinical cirrhosis was present in 
about half  of  the patients so the present data adds further 
information on severity of  liver disease associated with 
HDV genotype 1 in Pakistan.
It may not be difficult to predict whether HDV was 
acquired as a coinfection with HBV or as a superinfection 
in patients with existing chronic HBV infection. Natural 
history of  HDV infection shows that coinfection evolves 
to chronicity only in a small number of  patients and 
patients recover from both hepatitis B and D, while 
superinfection of  HDV leads to progressive disease and 
cirrhosis in approximately 80% of  cases[3]. Our patients 
were in the chronic phase. It can be assumed that most of  
our HDV RNA positive patients acquired the infection as 
a superinfection on hepatitis B.
In most cases of  HDV infection, HBV replication is 
suppressed to very low levels by HDV[20,21]. In our series, 
all the cases were negative for HBV DNA except three 
who were positive for HBV DNA, HBe antigen and HDV 
RNA. It seems that HBV replication is not suppressed 
RNA detected RNA not detected 
(n  = 23) (n = 16)
Male:Female 20:3 14:4
Age (yr) 29.7 ± 12.8 36.8 ± 15.2
Clinical cirrhosis 12 (52%)   7 ((44%)
Decompensated disease   5 (22%)   3 (19%)
Normal ultrasound and ALT   2 (9%)   4 (25%)
HBe antigen   3 (13%)   1 (6%)
HBV DNA   3 (13%)   0
Bilirubin (mg/dL)   1.8 ± 2.0   2.9 ± 5.6
ALT (U/L)    88 ± 45  125 ± 199
AST (U/L)    81 ± 52  150 ± 280
GGT U/L    99 ± 121    49 ± 31
ALP (U/L)  124 ± 56  100 ± 31
Albumin (g/dL)   3.4 ± 0.7   3.4 ± 0.9
Hemoglobin (g/dL) 12.3 ± 2.0 12.9 ± 1.8
Total leucocyte count (× 109/L)   6.1 ± 2.0   5.0 ± 1.8
Platelets (× 109/L)  143 ± 84  157 ± 85
INR   1.3 ± 0.2   1.2 ± 0.1
Table 1  Characteristics of hepatitis delta patients
ALT: alanine aminotransferase; AST: aspartate aminotransferase; GGT: 
gamma glutamyl transpeptidase; ALP: alkaline phosphatase; INR: 
international normalization ratio. Values are means ± SD, or n (%). There are 
no statistically significant differences among the two groups.
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by the presence of  HDV RNA in a subset of  subjects. A 
more ominous course toward liver decompensation has 
been documented in patients with active HBV and HDV 
replication[15] with each virus contributing to the liver 
damage, thereby resulting in more severe liver disease[22]. 
All the three of  our patients who were both HBV DNA 
and HDV RNA positive, had clinical cirrhosis.
Our patients with detectable HDV RNA were younger 
than patients with undetectable RNA. Absence of  HDV 
RNA in our 16 (41%) patients signifies that a proportion 
of  patients lose the virus with increasing age or viral titres 
become too low to be detectable by the assay we use. 
Four patients with undetectable RNA and two patients 
with detectable RNA had normal ALT and ultrasound 
abdomen. These patients were HBV DNA negative. The 
former four represent spontaneous recovery while later 
two were probably the asymptomatic carriers. This state 
has been reported previously[15,23].
In summary, HDV genotype I  is prevalent in our 
patients. HDV may infect at any age, usually young adult 
males. With time, some of  the patients become a HDV 
RNA negative or an asymptomatic carrier. Most of  the 
patients have suppressed HBV DNA replication. A signifi-
cant number of  patients have cirrhosis.
REFERENCES
1 Gaeta GB, Stornaiuolo G, Precone DF. Type B and D viral 
hepatitis: epidemiological changes in Southern Europe. Forum 
(Genova) 2001; 11: 126-133
2 Polish LB, Gallagher M, Fields HA, Hadler SC. Delta hepatitis: 
molecular biology and clinical and epidemiological features. 
Clin Microbiol Rev 1993; 6: 211-229
3 Rizzetto M, Smedile A. Hepatitis D. In:Schiff ER, Sorrell MF, 
Maddrey WC editors.Schiff's diseases of the liver. 9th ed. 
Lippincott Williams & Wilkins Philadelphia, 2003: 863-875
4 Rizzetto M, Verme G, Recchia S, Bonino F, Farci P, Aricò S, 
Calzia R, Picciotto A, Colombo M, Popper H. Chronic hepatitis 
in carriers of hepatitis B surface antigen, with intrahepatic 
expression of the delta antigen. An active and progressive 
disease unresponsive to immunosuppressive treatment. Ann 
Intern Med 1983; 98: 437-441
5 Mumtaz K, Hamid SS, Adil S, Afaq A, Islam M, Abid S, Shah 
HA, Jafri W. Epidemiology and clinical pattern of hepatitis 
delta virus infection in Pakistan. J Gastroenterol Hepatol 2005; 
20: 1503-1507
6 Hsu SC, Wu JC, Sheen IJ, Syu WJ. Interaction and replication 
activation of genotype I and II hepatitis delta antigens. J Virol 
2004; 78: 2693-2700
7 Shakil AO, Hadziyannis S, Hoofnagle JH, Di Bisceglie AM, 
Gerin JL, Casey JL. Geographic distribution and genetic 
variability of hepatitis delta virus genotype I. Virology 1997; 
234: 160-167
8 Farci P. Delta hepatitis: an update. J Hepatol 2003; 39 Suppl 1: 
S212-S219
9 Wu JC , Choo KB, Chen CM, Chen TZ, Huo TI, Lee SD. 
Genotyping of hepatitis D virus by restriction-fragment length 
polymorphism and relation to outcome of hepatitis D. Lancet 
1995; 346: 939-941
10 Watanabe H, Nagayama K, Enomoto N, Chinzei R, Yamashiro 
T, Izumi N, Yatsuhashi H, Nakano T, Robertson BH, Nakasone 
H, Sakugawa H, Watanabe M. Chronic hepatitis delta 
virus infection with genotype IIb variant is correlated with 
progressive liver disease. J Gen Virol 2003; 84: 3275-3289
11 Casey JL, Brown TL, Colan EJ, Wignall FS, Gerin JL. A 
genotype of hepatitis D virus that occurs in northern South 
America. Proc Natl Acad Sci USA 1993; 90: 9016-9020
12 Flodgren E, Bengtsson S, Knutsson M, Strebkova EA, Kidd 
AH, Alexeyev OA, Kidd-Ljunggren K. Recent high incidence 
of fulminant hepatitis in Samara, Russia: molecular analysis of 
prevailing hepatitis B and D virus strains. J Clin Microbiol 2000; 
38: 3311-3316
13 Ivaniushina V, Radjef N, Alexeeva M, Gault E, Semenov S, 
Salhi M, Kiselev O, Dény P. Hepatitis delta virus genotypes I 
and II cocirculate in an endemic area of Yakutia, Russia. J Gen 
Virol 2001; 82: 2709-2718
14 Gupta BP, Jayasuryan N, Jameel S. Direct detection of 
hepatitis B virus from dried blood spots by polymerase chain 
reaction amplification. J Clin Microbiol 1992; 30: 1913-1916
15 Rosina F, Conoscitore P, Cuppone R, Rocca G, Giuliani A, 
Cozzolongo R, Niro G, Smedile A, Saracco G, Andriulli 
A, Manghisi OG, Rizzetto M. Changing pattern of chronic 
hepatitis D in Southern Europe. Gastroenterology 1999; 117: 
161-166
16 Abbas Z, Muzaffar R, Siddiqui A, Naqvi SA, Rizvi SA. Genetic 
variability in the precore and core promoter regions of hepatitis 
B virus strains in Karachi. BMC Gastroenterol 2006; 6: 20
17 Niro GA, Smedile A, Andriulli A, Rizzetto M, Gerin JL, Casey 
JL. The predominance of hepatitis delta virus genotype I 
among chronically infected Italian patients. Hepatology 1997; 
25: 728-734
18 Altuğlu I, Ozacar T, Sertoz RY, Erensoy S. Hepatitis delta 
virus (HDV) genotypes in patients with chronic hepatitis: 
molecular epidemiology of HDV in Turkey. Int J Infect Dis 
2007; 11: 58-62
19 Saudy N, Sugauchi F, Tanaka Y, Suzuki S, Aal AA, Zaid 
MA, Agha S, Mizokami M. Genotypes and phylogenetic 
characterization of hepatitis B and delta viruses in Egypt. J 
Med Virol 2003; 70: 529-536
20 Krogsgaard K, Kryger P, Aldershvile J, Andersson P, Sørensen 
TI, Nielsen JO. Delta-infection and suppression of hepatitis B 
virus replication in chronic HBsAg carriers. Hepatology 1987; 7: 
42-45
21 Farci P, Karayiannis P, Lai ME, Marongiu F, Orgiana G, 
Balestrieri A, Thomas HC. Acute and chronic hepatitis delta 
virus infection: direct or indirect effect on hepatitis B virus 
replication? J Med Virol 1988; 26: 279-288
22 Smedile A, Rosina F, Saracco G, Chiaberge E, Lattore V, 
Fabiano A, Brunetto MR, Verme G, Rizzetto M, Bonino F. 
Hepatitis B virus replication modulates pathogenesis of 
hepatitis D virus in chronic hepatitis D. Hepatology 1991; 13: 
413-416
23 Wu JC, Li CS, Chen CL, Sheng WY, Lee SD, Lo KJ. Factors 
associated with viremia and elevated transaminase levels in 
asymptomatic hepatitis D virus-infected risk groups. J Med 
Virol 1994; 42: 86-90
                             S- Editor  Liu Y    L- Editor  Li M    E- Editor  Liu Y
Moatter T et al . Hepatitis delta in Karachi                                                                                                        2607
www.wjgnet.com
